Cui J, Heavey J, Lin L, Klein EY, Madden GR, Sifri CD, Lewis B, Vullikanti AK, Prakash BA. Modeling relaxed policies for discontinuation of methicillin-resistant
Staphylococcus aureus contact precautions.
Infect Control Hosp Epidemiol 2024;
45:833-838. [PMID:
38404133 PMCID:
PMC11439595 DOI:
10.1017/ice.2024.23]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 11/15/2023] [Accepted: 01/05/2024] [Indexed: 02/27/2024]
Abstract
OBJECTIVE
To evaluate the economic costs of reducing the University of Virginia Hospital's present "3-negative" policy, which continues methicillin-resistant Staphylococcus aureus (MRSA) contact precautions until patients receive 3 consecutive negative test results, to either 2 or 1 negative.
DESIGN
Cost-effective analysis.
SETTINGS
The University of Virginia Hospital.
PATIENTS
The study included data from 41,216 patients from 2015 to 2019.
METHODS
We developed a model for MRSA transmission in the University of Virginia Hospital, accounting for both environmental contamination and interactions between patients and providers, which were derived from electronic health record (EHR) data. The model was fit to MRSA incidence over the study period under the current 3-negative clearance policy. A counterfactual simulation was used to estimate outcomes and costs for 2- and 1-negative policies compared with the current 3-negative policy.
RESULTS
Our findings suggest that 2-negative and 1-negative policies would have led to 6 (95% CI, -30 to 44; P < .001) and 17 (95% CI, -23 to 59; -10.1% to 25.8%; P < .001) more MRSA cases, respectively, at the hospital over the study period. Overall, the 1-negative policy has statistically significantly lower costs ($628,452; 95% CI, $513,592-$752,148) annually (P < .001) in US dollars, inflation-adjusted for 2023) than the 2-negative policy ($687,946; 95% CI, $562,522-$812,662) and 3-negative ($702,823; 95% CI, $577,277-$846,605).
CONCLUSIONS
A single negative MRSA nares PCR test may provide sufficient evidence to discontinue MRSA contact precautions, and it may be the most cost-effective option.
Collapse